How to Get Zepbound for Weight Loss: Your Comprehensive Guide

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Getting Zepbound starts with a prescription from a licensed clinician, and the prescription is only appropriate if you meet the criteria written into the label. Per the Zepbound prescribing information, it is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition — and separately, to treat moderate to severe obstructive sleep apnea in adults with obesity. There is no legitimate route to Zepbound that skips a clinician. Everything below is about what that clinician will be looking at, and what happens after.

What the Label Says About Who Qualifies

The Zepbound labeling defines obesity as a body mass index of 30 kg/m² or greater, and overweight as a BMI of 27 to under 30 kg/m² accompanied by at least one weight-related comorbid condition. Those thresholds are not arbitrary marketing lines — they define the population in which the medication's benefit-risk balance was evaluated and accepted by the FDA.

The obstructive sleep apnea indication is separate and specific: moderate to severe OSA in adults with obesity. That distinction has practical consequences, because a person who qualifies under one indication may be evaluated very differently under the other, including how coverage is requested.

What a Prescriber Is Actually Screening For

Eligibility is not only about BMI. Zepbound's labeling carries a boxed warning stating that in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. The product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients with known serious hypersensitivity to tirzepatide or its excipients.

A thorough intake therefore covers personal and family endocrine history, prior pancreatitis, gallbladder disease, gastrointestinal conditions, pregnancy plans, and the full list of medications you already take. This is why a legitimate telehealth pathway asks a great many questions before anyone writes anything, and why a service that asks almost nothing should worry you.

The Evidence That Earned the Approval

The weight-management approval rests on the SURMOUNT program. SURMOUNT-1 ran 72 weeks in 2,539 adults with obesity or overweight, excluding people with diabetes, and reported mean weight changes of −15.0%, −19.5%, and −20.9% across the three doses studied versus −3.1% with placebo.

A later head-to-head trial put the question directly. SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or the maximum tolerated dose of semaglutide, subcutaneously once weekly for 72 weeks. Least-squares mean percent weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide, with waist circumference reductions of 18.4 cm and 13.0 cm respectively. Gastrointestinal adverse events were the most common in both groups, mostly mild to moderate, and occurred primarily during dose escalation.

Routes to a Prescription

There are three realistic paths, and they differ mainly in how much workup accompanies the visit. Primary care is the most common and integrates with the rest of your record. Obesity medicine and endocrinology specialists bring more depth on comorbidity management and on what to do when response stalls. Telehealth is faster and is often the only practical option in areas with long specialist waits.

What none of these paths changes is the clinical substance. A prescriber is required to evaluate you as an individual, and a legitimate service — in person or remote — will collect history, review contraindications, and establish follow-up. Speed is a feature of the logistics, not a shortcut through the medicine.

Coverage Is the Hard Part, Not the Prescription

Because coverage follows indication, the question your plan is answering is narrower than "do you cover Zepbound." Anti-obesity medication coverage in commercial and employer plans is a benefit-design decision made plan by plan, frequently with prior authorization requiring documented BMI, documented weight-related conditions, and evidence of continued response at renewal. Medicare Part D is constrained differently: section 1860D-2(e)(2) of the Social Security Act incorporates section 1927(d)(2), which permits exclusion of agents used for weight loss.

The obstructive sleep apnea indication is worth raising with your prescriber if it applies to you, because it is a medically accepted indication that is not weight loss. Whether it changes your particular plan's answer is something only your plan can tell you in writing.

Why the Compounded Landscape Changed

For a period during the shortage, compounded tirzepatide was widely available under FDA enforcement discretion. That discretion ended in 2025 — with deadlines of February 18 and March 19, 2025 for tirzepatide depending on the type of compounder — and the landscape narrowed considerably as a result.

Compounded tirzepatide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. It is not a generic version of Zepbound or Mounjaro; neither has an approved generic. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient, which is precisely what distinguishes it from material sold online as a research chemical. Anyone offering you tirzepatide without a prescription is not operating inside that framework.

What Getting It Actually Asks of You

Both approved indications are written as adjuncts — Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity. That phrasing is part of the approved use, not a disclaimer bolted on afterward. The trials that produced those results ran for 72 weeks alongside lifestyle intervention.

Expect ongoing follow-up rather than a single transaction: periodic review of response, tolerability, and any new symptoms, and a plan for what happens if the response is smaller than hoped. Every question about how the medication is handled, escalated, or stored belongs to your pharmacy label and your prescriber, who know your full clinical picture.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Who is eligible for Zepbound according to the label?

The Zepbound prescribing information indicates it, alongside a reduced-calorie diet and increased physical activity, for adults with obesity defined as a BMI of 30 kg/m² or greater, or adults with overweight at a BMI of 27 to under 30 kg/m² with at least one weight-related comorbid condition. It is separately indicated to treat moderate to severe obstructive sleep apnea in adults with obesity. Your prescriber determines whether you qualify.

Can I get Zepbound without seeing a clinician?

No. Zepbound is a prescription medication and there is no legitimate route that bypasses a licensed prescriber. A proper intake screens for the labeled contraindications, which include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, plus relevant history such as pancreatitis, gallbladder disease, and current medications. A service that asks very little should be treated with suspicion.

Is Zepbound more effective than semaglutide?

In SURMOUNT-5, a 72-week head-to-head trial in 751 adults with obesity but without type 2 diabetes, the least-squares mean percent weight change was −20.2% with maximum tolerated tirzepatide versus −13.7% with maximum tolerated semaglutide, with waist circumference falling 18.4 cm versus 13.0 cm. Group averages are not individual predictions, and tolerability differs from person to person.

Why is Zepbound coverage so inconsistent between plans?

Coverage attaches to indications and benefit design, not to molecules. Commercial and employer plans decide anti-obesity medication coverage plan by plan, usually with prior authorization requiring documented BMI and weight-related conditions. Medicare Part D operates under a statute that permits exclusion of agents used for weight loss. Ask your plan for its written prior-authorization criteria rather than assuming a blanket answer.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. It is not a generic version of Zepbound or Mounjaro, since neither has an approved generic. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. FDA enforcement discretion for compounded tirzepatide ended in 2025.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.